Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

By T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla and 11 more. JAMA Oncology, 2020

898 citations recorded by the source corpus.

Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib? Findings In the CheckMate 040 randomized clinical trial of nivolumab plus ipilimumab in patients with advanced hepatocellular cancer previously treated with sorafenib, patients were randomized 1:1:1 to 3 different treatment arms to evaluate different dosing regimens. Investigator-assessed objective response rate was greater than 30% across treatment arms, and the combination of nivolumab plus ipilimumab led to high overall survival rates and had a manageable safety profile. Meaning The manageable safety profile and promising response rates observed in this study support further investigation of nivolumab plus ipilimumab as a treatment option for this patient population.

Subfields: Hepatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/e8c0679fc3eb682e40e2daac3d4dae2e1562dce2